Allogene Therapeutics Investors
Allogene Therapeutics is a biotechnology company located in South San Francisco, California, specializing in the development of allogeneic CAR T-cell therapies for cancer treatment Founded in 2017, the company has established itself as a leader in the field of immuno-oncology Allogene Therapeutics has successfully raised significant investment totaling $288 million to advance its innovative therapeutic programs The organization collaborates with various government offices and university programs to enhance research and development efforts in cellular therapies With a strong commitment to improving patient outcomes, Allogene Therapeutics continues to drive advancements in the treatment of hematologic malignancies and solid tumors
Investors
Founded Date:
2017
Headquarters:
USA
Technology:
Сancer Diagnostics
Industry:
FemTech
Estimated Revenue:
$1M to $10M
Funding Status:
IPO
Investor Type:
Government Offices & University Programs